Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

The Marker State Space (MSS) method for classifying clinical samples.

Fallon BP, Curnutte B, Maupin KA, Partyka K, Choi S, Brand RE, Langmead CJ, Tembe W, Haab BB.

PLoS One. 2013 Jun 4;8(6):e65905. doi: 10.1371/journal.pone.0065905. Print 2013.

2.

Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.

Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, Diamandis EP.

BMC Cancer. 2013 Sep 3;13:404. doi: 10.1186/1471-2407-13-404.

3.

Prospects for developing an accurate diagnostic biomarker panel for low prevalence cancers.

Firpo MA, Boucher KM, Mulvihill SJ.

Theor Biol Med Model. 2014 Aug 5;11:34. doi: 10.1186/1742-4682-11-34.

4.

Development of serum parameters panels for the early detection of pancreatic cancer.

Zhang P, Zou M, Wen X, Gu F, Li J, Liu G, Dong J, Deng X, Gao J, Li X, Jia X, Dong Z, Chen L, Wang Y, Tian Y.

Int J Cancer. 2014 Jun 1;134(11):2646-55. doi: 10.1002/ijc.28584. Epub 2013 Nov 19.

5.

Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis.

Chang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, Fisher GA, Le QT, Chang DT, Ji H, Koong AC.

J Transl Med. 2009 Dec 11;7:105. doi: 10.1186/1479-5876-7-105.

6.

MicroRNA biomarkers in whole blood for detection of pancreatic cancer.

Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK, Johansen JS.

JAMA. 2014 Jan 22-29;311(4):392-404. doi: 10.1001/jama.2013.284664.

PMID:
24449318
7.

MCentridFS: a tool for identifying module biomarkers for multi-phenotypes from high-throughput data.

Wen Z, Zhang W, Zeng T, Chen L.

Mol Biosyst. 2014 Nov;10(11):2870-5. doi: 10.1039/c4mb00325j.

PMID:
25099602
8.

Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.

Navaglia F, Fogar P, Basso D, Greco E, Padoan A, Tonidandel L, Fadi E, Zambon CF, Bozzato D, Moz S, Seraglia R, Pedrazzoli S, Plebani M.

Clin Chem Lab Med. 2009;47(6):713-23. doi: 10.1515/CCLM.2009.158.

PMID:
19426140
9.

Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.

Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, Conrad T, Witzigmann H, Weimann A, Schütte C, Hauss J, Büchler M, Thiery J.

Clin Cancer Res. 2009 Jun 1;15(11):3812-9. doi: 10.1158/1078-0432.CCR-08-2701. Epub 2009 May 26.

10.

A novel mixed integer programming for multi-biomarker panel identification by distinguishing malignant from benign colorectal tumors.

Zou M, Zhang PJ, Wen XY, Chen L, Tian YP, Wang Y.

Methods. 2015 Jul 15;83:3-17. doi: 10.1016/j.ymeth.2015.05.011. Epub 2015 May 15.

PMID:
25980368
12.

Usefulness of serum IgG4 in the diagnosis and follow up of autoimmune pancreatitis: A systematic literature review and meta-analysis.

Morselli-Labate AM, Pezzilli R.

J Gastroenterol Hepatol. 2009 Jan;24(1):15-36. doi: 10.1111/j.1440-1746.2008.05676.x. Epub 2008 Dec 2. Review.

PMID:
19067780
13.

A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer from benign pancreatic diseases.

Hayakawa T, Naruse S, Kitagawa M, Ishiguro H, Kondo T, Kurimoto K, Fukushima M, Takayama T, Horiguchi Y, Kuno N, Noda A, Furukawa T.

Int J Pancreatol. 1999 Feb;25(1):23-9.

PMID:
10211418
14.

Development of biomarker classifiers from high-dimensional data.

Baek S, Tsai CA, Chen JJ.

Brief Bioinform. 2009 Sep;10(5):537-46. doi: 10.1093/bib/bbp016. Epub 2009 Apr 3. Review.

PMID:
19346320
15.

Mixture classification model based on clinical markers for breast cancer prognosis.

Zeng T, Liu J.

Artif Intell Med. 2010 Feb-Mar;48(2-3):129-37. doi: 10.1016/j.artmed.2009.07.008. Epub 2009 Dec 14.

PMID:
20005686
16.

Characterization of renal allograft rejection by urinary proteomic analysis.

Clarke W, Silverman BC, Zhang Z, Chan DW, Klein AS, Molmenti EP.

Ann Surg. 2003 May;237(5):660-4; discussion 664-5.

17.

Identification of serum biomarker signatures associated with pancreatic cancer.

Wingren C, Sandström A, Segersvärd R, Carlsson A, Andersson R, Löhr M, Borrebaeck CA.

Cancer Res. 2012 May 15;72(10):2481-90. doi: 10.1158/0008-5472.CAN-11-2883.

18.

Current concepts of tumor markers in bladder cancer.

Droller MJ.

Urol Clin North Am. 2002 Feb;29(1):229-34. Review.

PMID:
12109349
19.

Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry.

Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M.

Clin Cancer Res. 2004 Feb 1;10(3):860-8.

Supplemental Content

Support Center